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Abstract
Accumulating evidence suggests a crucial role for the unfolded protein response (UPR) in Parkinson’s disease (PD). In this
study, we investigated the relevance of the UPR in a mouse model of chronic MPTP/probenecid (MPTP/P) injection, which
causes severe and persistent degeneration of dopaminergic neurons. Enhanced activation of the UPR branches, including
ATF6a and PERK/eIF2a/ATF4, was observed after MPTP/P injections into mice. Deletion of the ATF6a gene accelerated
neuronal degeneration and ubiquitin accumulation relatively early in the MPTP/P injection course. Surprisingly, astroglial
activation was strongly suppressed, and production of the brain-derived neurotrophic factor (BDNF) and anti-oxidative
genes, such as heme oxygenase-1 (HO-1) and xCT, in astrocytes were reduced in ATF6a 2/2 mice after MPTP/P injections.
Decreased BDNF expression in ATF6a 2/2 mice was associated with decreased expression of GRP78, an ATF6a-dependent
molecular chaperone in the ER. Decreased HO-1 and xCT levels were associated with decreased expression of the ATF4-
dependent pro-apoptotic gene CHOP. Consistent with these results, administration of the UPR-activating reagent
tangeretin (5,6,7,8,49-pentamethoxyflavone; IN19) into mice enhanced the expression of UPR-target genes in both
dopaminergic neurons and astrocytes, and promoted neuronal survival after MPTP/P injections. These results suggest that
the UPR is activated in a mouse model of chronic MPTP/P injection, and contributes to the survival of nigrostriatal
dopaminergic neurons, in part, through activated astrocytes.
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Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative
disease pathologically characterized by the selective loss of
nigrostriatal dopaminergic neurons and the presence of protein
aggregates, known as Lewy bodies [1]. Although the etiology of
PD is not fully understood, several genetic and environmental
factors have been discovered that are utilized to model PD in
experimental animals [2]. 1-Methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP), an inhibitor of mitochondrial complex I,
induced human Parkinsonism [3], and has, therefore, been widely
used to generate a PD model in animals. MPTP is highly lipophilic
and crosses the blood-brain barrier. In the brain, it is converted to
the active form, 1-methyl-4-phenylpyridinium (MPP+) by astro-
cytes, and is taken up by dopaminergic neurons through the
dopamine transporter (DAT). Accumulating evidence suggests
that, compared with acute and subacute MPTP injection, chronic
administration of MPTP with probenecid (MPTP/P) into mice
causes more severe neurodegeneration and dopamine (DA)
depletion that resembles human PD [4,5].
Although MPTP causes oxidative stress and energy depletion
because of impaired mitochondrial function, recent studies suggest
that MPTP also causes endoplasmic reticulum (ER) stress, a type
of intracellular stress that is characterized by the accumulation of
unfolded proteins in the ER. ER stress occurs when cells are in
conditions such as glucose starvation (energy depletion), oxygen
deprivation, protein modification inhibition, and disturbance of
Ca2+ homeostasis. Eukaryotic cells respond to ER stress by
activating a set of pathways known as the unfolded protein
response (UPR) [6]. In mammals, the UPR is transmitted through
3 types of sensor proteins; double-stranded RNA-activated protein
kinase (PKR)–like ER kinase (PERK), inositol-requiring enzyme
1a (Ire1a), and activating transcription factor 6a (ATF6a) [6].
Ire1a and ATF6a downstream genes include molecular chaper-
ones in the ER, such as glucose-regulated protein78 (GRP78), and
oxygen-regulated protein 150 (ORP150), and ER-associated
degradation (ERAD) molecules such as Derlins, ER degradation
enhancing alpha-mannosidase-like protein (EDEM), and homo-
cysteine-inducible endoplasmic reticulum stress protein (Herp). In
PLOS ONE | www.plosone.org 1 October 2012 | Volume 7 | Issue 10 | e47950
contrast, PERK downstream genes include eukaryotic translation
initiation factor 2 (eIF2a), which suppresses general protein
synthesis to reduce protein loads into the ER, and activating
transcription factor 4 (ATF4), which upregulates the expression of
anti-oxidative genes such as heme oxygenase 1 (HO-1) and
cystine/glutamate antiporter (xCT). PERK also upregulates the
pro-apoptotic transcriptional factor C/EBP homologous protein
(CHOP) [7]. Cell culture models [8,9] and the acute MPTP
injection models [10,11] demonstrated the UPR has important
roles in promoting neuronal survival against MPTP neurotoxicity.
Furthermore, a recent report demonstrated that MPP+-associated
oxidative stress enhanced the interaction between phosphorylated
p38 mitogen-activated protein kinase (p38MAPK) and ATF6a,
causing increased transcriptional activity of ATF6a [12]. These
findings suggest an important communication between the
oxidative stress response and the UPR in PD pathogenesis.
We initiated this study by estimating the UPR activation status
after chronic MPTP/P injections into wild-type mice. We
compared neurodegeneration, protein aggregation, and glial
activation levels between wild-type and ATF6a 2/2 mice.
Finally, we estimated the neuroprotective property of the UPR-
activating compound, tangeretin (5,6,7,8,49-pentamethoxyflavone;
IN19), in the mouse model of chronic MPTP/P injection.
Materials and Methods
Ethics Statement
All animal care and handling procedures were approved by the
Animal Care and Use Committee of Kanazawa University (No.
71241-1).
Materials
MPTP and Cremophore EL were purchased from Sigma (St
Louis, MO). Probenecid and dimethy sulfoxide (DMSO) were
purchased from Wako Chemicals (Osaka, Japan). The UPR-
activating compound tangeretin (IN19) was isolated as described
previously [13].
Mice and Chronic MPTP/P Injection PD Model
ATF6a 2/2 mice were generated as described previously [14],
and backcrossed to the C57BL/6 strain more than 8 times. Wild-
type and ATF6a 2/2 male mice (aged 12–15 weeks and
weighing 26–30 g) were used for the experiments. The chronic
MPTP/P injection PD model was created as described previously
with some modifications. In brief, mice were administered MPTP
(20 mg/kg in saline, subcutaneously) and probenecid (250 mg/kg
in DMSO, intraperitoneally) twice a week for 5 weeks [4]. At the
indicated times, brain samples were prepared for histological
analyses, RT-PCR/quantitative real time RT-PCR (qRT-PCR)
and Western blotting as described. In some experiments, mice
were administered tangeretin (10 mg/kg, per oral, in saline
including 10% Cremophore EL and 10% DMSO) or the
dissolving solution (vehicle) 24 h and 2 h before MPTP/P
injections [11].
RT-PCR and Quantitative Real Time RT-PCR (qRT-PCR)
Total RNA was extracted from the ventral midbrain or caudate
putamen (CPu) of each mouse using RNAzolHRT (Molecular
Research Center Inc, Cincinnati, OH). RT reactions containing
1 mg of total RNA were performed using PrimeScript (Takara,
Shiga, Japan). The individual cDNA species were amplified in
a reaction mixture containing 1 unit of Taq DNA polymerase
(Takara) and specific primers for ATF6, GRP78, ORP150, ATF4,
HO-1, CHOP, X-box binding protein 1 (XBP-1), Sec61b, GFAP,
Iba1, andb-actin as described previously. In some experiments,
cDNA derived from cultured astrocytes treated with tunicamycin
for 8 h [15] was used as a positive control for XBP1 activation. For
qRT-PCR, cDNA was amplified with THUNDERBIRDTM
SYBR qPCRH Mix (TOYOBO CO, LTD, Osaka, Japan) by
using specific primers for brain-derived neurotrophic factor
(BDNF), leukemia inhibitory factor (LIF), interleukin-6 (IL-6),
GRP78, ORP150, CHOP, xCT, manganese superoxide dismu-
tase (MnSOD), and b-actin. The comparative Ct method was used
for data analyses with MxPro 4.10 (Agilent Technologies, Santa
Clara, CA). Values for each gene were normalized to b-actin
expression levels.
Western Blotting and ELISA
Brain samples from the ventral midbrain or CPu were
solubilized in buffer containing 1% NP40, 0.1% SDS, and 0.2%
deoxycholate, and subjected to Western blotting with following
antibodies: BDNF (Epitomics, Burlingame, CA), GRP78 (Stress-
Gen, Victoria, British Columbia, Canada), HO-1 (Abcam, Cam-
bridge, UK), xCT (Thermo Scientific, Rockford, IL), GLT-1
(Millipore, Temecula, CA), LIF (Santa Cruz Biotechnology, Santa
Cruz, CA), GFAP (Dako, Glostrup, Denmark) and b-actin
(Sigma). Primary antibody binding was visualized using alkaline
phosphatase-conjugated secondary antibodies or the ECL system
(GE Healthcare Bio-Sciences Corp., Piscataway, NJ). IL-6 levels in
the brain samples were measured using ELISA (eBioscience, San
Diego CA).
Histological and Immunohistochemical Analyses
Brains were removed from mice after perfusion with 4%
paraformaldehyde, and postfixed in the same fixative for 4 hours
at 4uC. After cryoprotected in 30% sucrose, brains were cut in
serial coronal 10 mm-thick sections containing the CPu (from
Bregma+1.34 mm to Bregma+0.26 mm) and the midbrain cover-
ing the whole SNpc (from Bregma-2.80 mm to Bregma-3.80 mm)
on a cryostat, and mounted in series on ten slides (around ten
sections were mounted on each slide). One out of these ten slides,
representing a set of sections 100 mm apart, were processed for
immunohistochemistry, and the negative control, in which the
primary antibody was omitted, was performed in parallel with
each procedure. Primary antibodies used were; anti-TH (Sigma),
anti-GRP78, anti-HO-1, anti-GLT-1, anti-Ubiquitin (StressGen),
anti-cleaved caspase 3 (Cell Signaling Technology, Danvers, MA),
anti-BDNF, anti-GFAP, anti-Iba1. In some cases, the cell nucleus
was visualized with DAPI (Sigma), and Cresyl violet (Sigma) was
used for counterstaining. Appropriate Alexa Fluor 488, Cy3-
conjugated IgG or peroxidase-conjugated IgG was used as
a secondary antibody. Confocal images were obtained by using
Nikkon EZ-C1. In the process of apoptosis, cleaved caspase 3 was
observed both in the cytosol and nucleus. Expression of GRP78,
ORP150, HO-1, and BDNF was immunohistochemically detected
mainly in the cell body of neurons and/or astrocytes, and that of
GLT-1 was detected in the process of astrocytes.
Image Quantification
Quantification of the RT-PCR, Western Blotting, and immu-
nohistochemical analyses were performed using Image J (version
1.42, Wayne Rasband, National Institutes of Health). The number
of TH positive neurons in the SNpc was counted in five
representative sections out of ten sections mounted on one slide,
which covered the whole SNpc. Statistical analyses were
performed using Bonferroni/Dunn test following a one-way
ANOVA.
Unfolded Protein Response in Parkinson’s Disease
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Figure 1. The unfolded protein response (UPR) in a mouse model of chronic MPTP/P injection. A, Neurodegeneration (I) and UPR
activation (II, III, IV) in the SNpc after MPTP/P injections. Brain sections, including the SN from wild-type mice injected with or without MPTP/P were
immunostained with the TH, GRP78, GFAP, and Iba1 antibodies. Scale bars = 50 mm (I), 30 mm (II), 20 mm (III), 20 mm (IV). B, Gene expression in the
UPR branches after MPTP/P injections. Total RNA (1 mg) isolated from the ventral midbrain of mice was subjected to RT-PCR with specific primers for
ATF6a-target genes (I), ATF4-target genes (II), XBP1-target genes, and b-actin (III). The far right lane in (III) indicates the unspliced and spliced form of
the XBP1 from cultured astrocytes treated with thapsigargin (an ER stressor). The relative intensity of the bands derived from the mice without MPTP/
P injection is designated as one. Values shown are the mean 6 S.D. *P,0.05, **P,0.01 compared with mice without MPTP/P administration (n = 4).
doi:10.1371/journal.pone.0047950.g001
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Figure 2. Accelerated neurodegeneration and Ub accumulation in ATF6a2/2mice after MPTP/P injection. A, TH immunereactivity (I, II)
and activated caspase 3 (III) after MPTP/P injections. Brain sections, including the SN (I, III) or CPu (II), from wild-type and ATF6a 2/2 mice that were
injected with or without MPTP/P were immunostained with TH and activated caspase 3 antibodies. The number of TH-positive neurons in the SNpc (I)
and TH or activated caspase3 intensity in the CPu (II) are shown in the graph. In III, the nuclei are stained with DAPI. Arrows indicate activated caspase
Unfolded Protein Response in Parkinson’s Disease
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Results
UPR in the Chronic MPTP/P Injection PD Model
When MPTP/P was injected into C57BL/6 wild-type mice, the
number of TH-positive dopaminergic neurons in the SNpc and
the intensity of TH in the CPu gradually decreased (Fig. 1 A I,
Fig. 2 A I, II). This result indicates degeneration of the nigrostriatal
dopaminergic neurons in this model. Further immunohistochem-
ical studies revealed increased expression of the UPR-target gene
GRP78 after MPTP/P injections in TH-positive dopaminergic
neurons (Fig. 1 A II) and GFAP-positive activated astrocytes (Fig. 1
A III), but not in Iba1-positive microglia (Fig. 1 A IV). To evaluate
the activation status of the 3 major UPR pathways after MPTP/P
injections, we analyzed the expressions of genes involved in each
pathway by using RT-PCR (Fig.1 B I, II, III). The transcripts of
ATF6a and its downstream genes, such as GRP78 and ORP150,
were enhanced 2.5, 2.3, and 2.4 fold, respectively, 8 h after the
first MPTP/P injection. The increased expression tended to last
until at least fifth MPTP/P injection (Fig. 1 B I). Transcripts of
ATF4 and its downstream genes, such as CHOP and HO-1,
which is also a target of NF-E2-related factor 2 (Nrf2), were
enhanced 2.3, 2.5, and 7.6 fold, respectively, 8 h after the first
MPTP/P injection. However, the expression levels dropped to 1.7,
1.4, and 3.9 fold, respectively, 24 h after the first injection (Fig. 1 B
II). In contrast, the Ire1/XBP-1 pathway, and XBP-1, which can
be detected by the altered splicing pattern [6], was not activated.
In addition, the downstream gene Sec61b was not upregulated
after MPTP/P injection (Fig. 1 B III).
Accelerated Neurodegeneration and Ub Accumulation in
ATF6a 2/2 Mice after MPTP/P Injections
To evaluate the neuroprotective role of the UPR in the chronic
MPTP/P injection model, we immunehistochemically compared
nigrostriatal neuronal degeneration between wild-type and ATF6a
2/2 mice (Fig. 2 A I, II). In the control condition (without
MPTP/P administration), the number of TH-positive neurons in
the SNpc and the intensity of TH in the CPu were not significantly
different among the wild-type and ATF6a-deficient mice. In
contrast, in the early course of MPTP/P injections (2nd and 3rd
injections), the number of TH-positive neurons in the SNpc and
the intensity of TH in the CPu were significantly lower in ATF6a
2/2 mice compared to wild-type mice. Consistent with these
results, higher numbers of activated caspase-3-positive, TH-
positive neurons were observed in ATF6a 2/2 mice (74%)
compared to wild-type mice (47%; Fig. 2 A III). The specificity of
the antibody and the appropriate immunoreactivity of the antigen
were confirmed by the negative control experiment where primary
antibody was omitted (Fig. S 2 A) and the serial photograph of the
confocal images (Fig. S 2 B), respectively. In the later injections
(6th–10th injections), however, the nigrostriatal dopaminergic
neurons had degenerated to similar levels in both cohorts (Fig.2
A I, II). Egawa et al. recently demonstrated the presence of Ub-
positive inclusions in ATF6a 2/2 mice after acute MPTP
injection [12]. Therefore, we assessed Ub accumulation in our
model. In the control condition, slight Ub immunoreactivity in the
cell body was observed in TH-positive neurons of both cohorts
(Fig. 2 B I, upper row). However, after the 3rd MPTP/P injection,
Ub accumulation was observed in the degenerating dopaminergic
neurons in the ATF6a 2/2 SNpc, but not in the wild-type SNpc
(Fig. 2 B I, arrows). In 29% (4 of 14) of ATF6a 2/2 mice, Ub-
positive inclusions were observed in the neurons after 10th MPTP/
P injection (Fig. 2 B II), but not in wild-type neurons (data not
shown). These inclusions were negative or very weak for a-
synuclein immunoreactivity (Fig. 2 B III), as previously described
[12].
Impaired Astroglial Activation in ATF6a 2/2 mice after
MPTP/P Injections
Accelerated neurodegeneration was observed in ATF6a 2/2
mice predominantly when glial cells were activated (Fig. S1).
Therefore, glial activation was assessed in wild-type and ATF6a
2/2 mice. Immunohistochemical analyses in the SN and CPu
revealed that in the control condition, GFAP-positive astrocytes
were sparsely observed in both mouse cohorts (Fig. 3 A I, II,
arrows). However, in the period from the 2nd to 3rd MPTP/P
injection, the features of astroglial activation (enlarged cell bodies
and thick processes) in the SN and CPu were observed more
frequently in wild-type mice compared to ATF6a 2/2 mice
(Fig. 3 A I, II, 2nd and 3rd rows). In the wild-type SN, astrocytes
became enlarged in the SN pars reticulata (SNpr) first (arrow-
heads), and then penetrated into the SNpc (asterisks), but ATF6a
2/2 astrocytes were not enlarged after MPTP/P injections. In
the CPu, wild-type astrocytes near the lateral ventricle (arrows)
and corpus callosum (data not shown) became enlarged and,
almost simultaneously, spread over the CPu, but again, ATF6a
2/2 astrocytes were not enlarged after MPTP/P injections.
Consistent with the immunohistochemical observations, Western
blot analyses revealed enhanced GFAP expression in wild-type
mice, but not in ATF6a2/2mice, after the 2nd and 3rd MPTP/P
injections (Fig.4 C I). In contrast to high levels of astroglial
activation, microglial activation was modest in this model, and the
differences in the microglia morphology were not clear between
wild-type and ATF6a 2/2 mice after the 2nd MPTP/P injection
(Fig. 3 A II).
Activated astrocytes contribute to neuroprotection in several
ways, including neurotrophic factor synthesis, enhancement of
anti-oxidative systems, and glutamate metabolism [16,17]. There-
fore, we compared the expression of BDNF (a neurotrophic
factor), HO-1 (an anti-oxidative gene), and GLT-1 (a glutamate
transporter) in wild-type and ATF6a 2/2 mice. Immunohisto-
chemical analyses revealed that BDNF and HO-1 expression
(Fig. 3 B I, II), but not GLT-1 expression (Fig. S2 C), were higher
after MPTP/P injections in wild-type astrocytes compared with
ATF6a 2/2 astrocytes in the CPu.
Reduced UPR Levels and Gene Expression in ATF6a 2/2
Astrocytes after MPTP/P Injections
To determine whether impaired astroglial activation was
associated with reduced UPR levels in ATF6a 2/2 mice,
expression of astrocyte-derived neurotrophic factor (BDNF), anti-
3-positive, TH-positive neurons. The relative number of activated caspase 3-positive, TH-positive neurons in the SNpc are also shown in the graph.
Values shown are the mean6 S.D. Scale bars = 50 mm (I), 100 mm (II), 30 mm (III). *P,0.05, compared between wild-type and ATF6a2/2mice (n = 4).
B, Ub accumulation (I) and intracellular inclusion bodies (II) in ATF6a2/2 mice after MPTP/P injections. (I) Brain sections, including the SN, from mice
that were injected with or without MPTP/P were immunostainined with the TH and Ub antibodies. Nuclei were stained with DAPI. Note that in ATF6a
2/2 mice, Ub accumulation was observed in cells with reduced TH immunoreactivity (arrows). (II, III) Brain sections, including the SN, from ATF6a 2/
2 mice that were injected 10 times with MPTP/P were immunostained with the Ub (II) or a-synuclein antibody, followed by counterstaining with
cresyl violet. Arrows indicate Ub-positive inclusion bodies. Scale bars = 30 mm (I), 20 mm (II, III).
doi:10.1371/journal.pone.0047950.g002
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oxidative genes (HO-1, xCT, and MnSOD), astrogliosis-inducing
factors (LIF and IL-6), and the glutamate transporter (GLT-1) was
compared with the expression of ATF6a-dependent molecular
chaperones in the ER (GRP78 and ORP150) and the PERK/
ATF4-dependent pro-apoptotic transcriptional factor (CHOP).
Expression of the BDNF protein in ATF6a 2/2 mice was 62%
and 68% of that in wild-type mice in the control condition and
after the 3rd MPTP/P injection, respectively (Fig. 4 A I). Similarly,
expression of the GRP78 protein in ATF6a 2/2 mice was 60%
and 55% of that in wild-type mice in the control condition and
after the 3rd MPTP/P injection, respectively (Fig. 4 A I). The
expression level of BDNF, GRP78, and ORP150 mRNA in
ATF6a 2/2 mice was 71%, 77% and 79% of that in wild-type
mice in the control condition, and 150%, 74%, and 83% at
twenty-four hours after the 1st MPTP/P injection (Fig. 4 A II).
These results suggest that the deletion of the ATF6a gene may
suppress BDNF expression by transcriptional (as in the control
condition) and translational/posttranslational (as in the MPTP/P-
injected conditions) mechanisms.
Regarding the anti-oxidative genes, expression of the PERK/
ATF4-dependent genes, HO-1 and xCT, was lower in ATF6a 2/
2 mice than wild-type mice, at both the protein and mRNA level
after MPTP/P injection, although they were not significantly
different in the control conditions (Fig. 4 B I, II). Similar results
were obtained with CHOP (Fig. 4 B I, II). In contrast, expression
of the PERK/ATF4-independent anti-oxidative gene MnSOD
was not significantly different between wild-type and ATF6a 2/2
mice, either in the control or after MPTP/P injection (data not
shown).
Several cytokines and growth factors secreted from damaged
neurons or other cells in the brain can induce astroglial activation
[18]. Therefore, we examined the expression level of these genes in
wild-type and ATF6a 2/2 mice. LIF and IL-6 expression was
significantly enhanced, both at the protein (Fig. 4 C I, II) and
mRNA (Fig. 4 C III) level, after MPTP/P injection in wild-type
mice, but not in ATF6a 2/2 mice. Importantly, increased LIF
and IL-6 expression in wild-type mice preceded GFAP upregula-
tion (Fig. 4 C I). Although reduced expression of LIF and IL-6 is
likely not associated with reduced GRP78 or CHOP expression in
ATF6a 2/2 mice, these results suggest that ATF6a may
transcriptionally regulate the expression of astrogliosis-inducing
factors after MPTP/P injection.
Consistent with the immunohistochemical results, GLT-1
expression was not significantly different between wild-type and
ATF6a 2/2 mice in the control condition or after MPTP/P
injection (Fig. S2 D).
UPR Activation and Neuroprotection by IN19
We previously reported that IN19 activated the UPR and
protected dopaminergic neurons against acute MPTP administra-
tion [11]. In this study, we evaluated the neuroprotective property
of IN19 in the chronic MPTP/P injection model. Immunohisto-
chemical analyses revealed that IN19 administration (86IN19
administration p.o./2 weeks) upregulated the expression of
ORP150 (Fig. 5 A I, II) and GRP78 (Fig. S3 A) in TH-positive
dopaminergic neurons and GFAP-positive astrocytes without
reducing the number of TH-positive neurons or the intensity of
TH. RT-PCR analyses revealed enhanced activation of ATFa and
PERK/ATF4 pathways, but not of the Ire1/XBP1 pathway, in
IN19-administrated mice (Fig. 5 B I, II, III). Unlike MPTP/P
administration, IN19 administration did not upregulate GFAP or
Iba1 (Fig. 5 B IV), suggesting that the effect of IN19 on UPR was
not mediated by general neuronal damage. IN19 also enhanced
eIF2a phosphorylation in dopaminergic neurons (Fig. S3 B), as
previously described [11]. Next, we assessed the neuroprotective
property of IN19 after MPTP/P injections. When mice were given
IN19 (10 mg/kg, p.o. in saline, including 10% Cremophore EL
and 10% DMSO) 24 h and 2 h before MPTP/P injection, the
number of TH-positive neurons in the SN and the intensity of TH
in the CPu were significantly increased (Fig. 6 A). Consistently, the
number of activated caspase 3-positive, TH-positive neurons (Fig. 6
B) decreased in the SN, and expression of BDNF in the CPu
increased in the astrocytes of mice given IN19 after MPTP/P
injection (Fig. 6 C I, II). Importantly, expression of GFAP in the
CPu also mildly, but significantly, increased in mice given IN19
after MPTP/P injection (Fig. 6 C I, II), suggesting that IN19 may
protect dopaminergic neurons, at least in part, through the
activated astrocytes after MPTP/P administration.
Discussion
In this study, we first demonstrated the activation of the UPR in
a chronic MPTP/P injection model. Of the 3 UPR branches, the
ATF6a and PERK/eIF2a/ATF4 pathways were preferentially
activated after MPTP/P injections (Fig. 1 B). We also observed
a trend that the PERK/eIF2a/ATF4 pathway was highly
activated after the 1st MPTP/P injection (8 h after injection;
Fig. 1 B II), but the ATF6 pathway was activated for longer
periods over the course of the MPTP/P injections (1st through 5th
injections; Fig. 1 B I). These results are consistent with those of
previous reports demonstrating differential activation between the
3 UPR branches after PD-related stresses caused by MPP+ or 6-
OHDA in cultured cells [9,19]. Taken together with a recent
report, which demonstrated a direct link after MPP+ treatment
between p38 MAP kinase and ATF6a [12], these findings suggest
critical roles for the ATF6a and PERK/eIF2a/ATF4 pathways as
defense systems against PD-related neurotoxins.
Analyses of wild-type and ATF6a 2/2 mice showed acceler-
ated degeneration of the nigrostriatal neurons in ATF6a 2/2
mice (Fig. 2 A I, II, III) after the earlier MPTP/P injections (2nd
and 3rd injections), but not after the later injections (6th
through10th injections). Similarly, Ub accumulation was observed
in ATF6a 2/2 dopaminergic neurons after the early MPTP/P
injections (2nd and 3rd injections; Fig. 2 B I). However, Ub-positive
inclusions, which were abundantly observed in ATF6a 2/2 mice
after acute MPTP injection [12], were observed only in 29% of
ATF6a 2/2 mice after the last injection (10th injection; Fig. 2 B
II). These results suggest that ATF6a may contribute to neuronal
survival and protein aggregation regulation in the early stages, but
not in the late stages, of PD. Regarding the cell death pathways
Figure 3. Impaired astroglial activation in ATF6a2/2mice after MPTP/P injections. A, GFAP, TH, and Iba1 expression after MPTP/P
injections. Brain sections, including the SN (I) or CPu, (II) from wild-type and ATF6a2/2 mice that were injected with or without MPTP/P were
immunostained with GFAP, TH, and Iba1 antibodies. Nuclei were stained with DAPI. Arrows and arrowheads indicate non-activated and activated
astrocytes, respectively. Asterisks indicate activated astrocytes penetrating into the SNpc. Scale bars = 30 mm. B, BDNF (I) and HO-1 (II) expression in
astrocytes after MPTP/P injections. Brain sections, including the CPu, from wild-type and ATF6a 2/2mice that were injected with or without MPTP/P
were immunostained with the BDNF, HO-1, and GFAP antibodies. Nuclei were stained with DAPI. The relative intensity of BDNF (I) or HO-1 (II) in the
GFAP-positive cells is shown in the graph. The intensity of the signals derived from wild-type mice without MPTP/P injection is designated as one.
Values shown are the mean 6 S.D. *P,0.05, compared between wild-type and ATF6a2/2 mice (n = 4). Scale bars = 30 mm.
doi:10.1371/journal.pone.0047950.g003
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involved in our model, increased expression of activated caspase-3
was observed in ATF6a 2/2 dopaminergic neurons after
MPTP/P injections. However, the expression of CHOP, a medi-
ator of ER stress-induced cell death, was reduced in ATF6a 2/2
mice compared with wild-type mice after MPTP/P injections
(Fig. 4 A II, C II). These data suggest that the accelerated neuronal
Figure 4. Reduced UPR levels and gene expression in ATF6a2/2mice after MPTP/P injections. Protein expression of neurotrophic factor
(A I), anti-oxidative genes (B I), astrogliosis-inducing factor (C I, II), and the UPR-target genes (A I, B I). Protein extracts from brains (CPu) of wild-type or
ATF6a 2/2 mice that were injected or not injected with MPTP/P were subjected to Western blotting with the indicated antibodies (A I, B I, C I), or
subjected to IL-6 ELISA (C II). Relative intensities are shown in the graphs. The intensity of the genes from wild-type mice without MPTP/P
administration is designated as one. Values shown are the mean 6 S.D. *P,0.05, compared with mice without MPTP/P administration. #P,0.05,
compared between wild-type and ATF6a 2/2 brains (n = 4). Transcripts of neurotrophic factor (A II), anti-oxidative genes (B II), astrogliosis-inducing
factors (C III), and the UPR-target genes (A II, B II). Total RNA (1mg) isolated from wild-type or ATF6a 2/2 brains (CPu) at indicated times after 1st
MPTP/P injection was subjected to qRT-PCR with specific primers for the indicated genes. The relative intensity of the genes from wild-type mice not
administered MPTP/P is designated as one. Values shown are the mean 6 S.D. *P,0.05, **P,0.01, compared with the mice without MPTP/P
administration. #P,0.05, compared between wild-type and ATF6a 2/2 brains (n = 4).
doi:10.1371/journal.pone.0047950.g004
Figure 5. UPR in the brain after tangeretin (IN19) administration. A, UPR activation in dopaminergic neurons (I) and astrocytes (II) by IN19.
Brain sections, including SN from wild-type mice administered or not administered IN19 for 2 weeks (4 times/week) were immunostained with the
ORP150, TH, and GFAP antibodies. The relative intensity of ORP150 in the TH-positive cells (I) or the GFAP-positive cells (II) is shown in the graph. The
intensity of the signals derived from vehicle-administered mice is designated as one. Values shown are the mean6 S.D. *P,0.05, compared between
vehicle- and IN19-administered mice (n = 4). Scale bars = 30 mm (I), 20 mm (II). B, Gene expression in the UPR branches and gliosis after IN19
administration. Total RNA (1 mg) isolated from brain samples, including the ventral midbrain, with or without IN19 administration was subjected to
RT-PCR with specific primers for ATF6a-related genes (I), ATF4-related genes (II), XBP1-related genes and b-actin (III), gliosis-related genes (IV). The far
left lane in (III) indicates the unspliced and spliced form of the XBP1 from cultured astrocytes treated with thapsigargin (an ER stressor). Note that
XBP-1 transcripts were upregulated by IN19 administration, but they were not activated. The relative intensity of the bands derived from mice
without IN19 administration is designated as one. Values shown are the mean 6 S.D. *P,0.05, **P,0.01 compared with mice not administered
MPTP/P (n = 4).
doi:10.1371/journal.pone.0047950.g005
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Figure 6. IN19-mediated neuroprotection in a chronic MPTP/P injection model. A, The effect of IN19 on neurodegeneration after MPTP/P
injections. Brain sections, including the SN (upper row) or CPu (lower row), from wild-type mice that were injected or not injected with MPTP/P, in the
presence or absence of IN19, were immunostained with the TH antibody. The number of TH-positive neurons in the SNpc and TH intensity in the CPu
are shown in the graph. Values shown are the mean 6 S.D. *P,0.05, **P,0.01, compared with mice without MPTP/P administration. #P,0.05,
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death in ATF6a 2/2 dopaminergic neurons after MPTP/P
injection may include ER stress-induced, CHOP-independent
neuronal death. This is consistent with the finding of a previous
report demonstrating that null mutation of CHOP did not protect
against neuronal loss in a chronic MPTP/P model [20].
Interestingly, astroglial activation was strongly suppressed, and
biosynthesis of the neurotrophic factor BDNF and the anti-
oxidative gene heme oxygenase-1 (HO-1) was reduced in ATF6a
2/2 mice after MPTP/P injections (Fig. 3 B I, II). Astrocytes are
ubiquitous in the brain, and upon central nervous system insult,
undergo molecular and morphological changes, referred to as
reactive astrogliosis or astroglial activation [18]. Activated
astrocytes enhance the neuronal survival by secreting neurotrophic
factors or antioxidants, as well as by reducing glutamate levels in
extracellular spaces [16,17]. In our model, reduced BDNF
expression was observed in ATF6a 2/2 mice and was associated
with reduced GRP78 expression (Fig. 4 A, B). These results were
consistent with those of our previous reports that ATF6a-
dependent molecular chaperones, such as GRP78 and ORP150,
promote the maturation of neurotrophic factors in the ER [21,22].
Expression of the PERK/ATF4-dependent anti-oxidative genes
HO-1 and xCT, but not the PERK/ATF4-independent anti-
oxidative gene MnSOD was also reduced at both the protein and
mRNA level in ATF6a2/2mice after MPTP/P injections (Fig. 4
A). These results suggest that some of PERK/ATF4-dependent
anti-oxidative genes are also transcriptionally regulated by ATF6a,
similar to PERK/ATF4-dependent pro-apoptotic gene CHOP
[23]. Although it is currently unknown which steps in astroglial
activation are impaired in ATF6a 2/2 mice, it is possible that
extracellular signals including LIF and IL-6, from damaged
neurons or other cells in the brain, are too low to promote
activation in ATF6a 2/2 astrocytes. Alternatively, it is also
possible that enhanced levels of ER stress in ATF6a 2/2
astrocytes compromised intracellular signals which are important
for the astroglial activation, as was recently reported for
hepatocytes [24].
Consistent with the results from ATF6a 2/2 mice, adminis-
tration of the IN19 to wild-type mice enhanced UPR-target gene
expression, including ORP150 and GRP78, in both nigrastriatal
neurons and astrocytes, and facilitated neuronal survival after
MPTP/P injection. These results are consistent with those of
previous reports demonstrating that IN19 can distribute into the
brain after oral administration [25], and protect cells in both the
ER stress model and acute MPTP injection model [11,25].
Although IN19 alone did not cause astrogliosis (Fig. 5 B IV), IN19
administered in the course of MPTP/P injections enhanced
expression of GFAP (Fig. 6 C I, II) mildly, but significantly,
suggesting that IN19 may protect dopaminergic neurons, at least
in part, through the activated astrocytes after MPTP/P admin-
istration. A recent report demonstrated that Salubrinal, a com-
pound that regulates ER stress by activating the eIF2a/ATF4
pathway, attenuated disease manifestation in the A53T a-
synuclein-overexpressed PD model [26]. These results emphasize
the protective role of the UPR in PD.
In conclusion, we found that the UPR branches were activated
in a mouse model of chronic MPTP/P injection, and they
contributed to nigrostriatal neuronal survival, at least in part,
through activated astrocytes. Further studies to dissect the neuron-
glial association through the UPR should provide novel therapeu-
tic window for PD and other neurodegenerative diseases.
Supporting Information
Figure S1 Astrocyte and microglia activation in a mouse
model of chronic MPTP/P injection. Total RNA (1 mg)
isolated from brain samples, including the ventral midbrain, after
MPTP/P injections was subjected to RT-PCR with specific
primers for GFAP (activated astrocytes) and Iba1 (activated
microglia) as described in Fig. 1 B. The relative intensity of the
bands derived from mice without MPTP/P administration is
designated as one. Values shown are the mean 6 S.D. *P,0.05,
**P,0.01 compared with mice not administered MPTP/P (n= 4).
(TIF)
Figure S2 Immunohistochemical analysis of wild-type
and ATF6a 2/2 brains after MPTP/P injections. A,
Negative control experiment. Brain sections, including the SN
from wild-type and ATF6a 2/2 mice after MPTP/P injection,
were incubated with mouse anti-TH antibody, followed by
incubation with both anti-rabbit Alexa Fluor 488 and Cy3-
conjugated anti-mouse IgG. Scale bars = 30 mm (low mag.),
15 mm (high mag.).B, Serial photograph of activated caspase 3
in wild-type mice after MPTP/P injections. Brain sections,
including the SN from wild-type mice after MPTP/P injection,
were immunostained with TH and activated caspase 3 antibodies.
The nuclei are stained with DAPI. Scale bar = 15 mm. C,
Immunohistochemical analyses of GLT-1. Brain sections, in-
cluding the CPu, from wild-type and ATF6a 2/2 mice after
MPTP/P injections were immunostained with GLT-1 and GFAP
antibodies. Nuclei were stained with DAPI. Scale bar = 30 mm. D,
Western blot analyses for GLT-1. Protein extracts from brains
(CPu) of wild-type and ATF6a 2/2 mice that were injected or
not injected with MPTP/P were subjected to Western blot with
the GLT-1 antibody.
(TIF)
Figure S3 UPR activation and astrogliosis after tanger-
etin (IN19) administration. GRP78 expression (A), eIF2a
activation (B) in the SN. Brain sections, including the SN, from
wild-type mice administered or not administered IN19 for 2 weeks
(4 times/week) were immunostained with the GRP78, phosphor-
ylated eIF2a, and TH antibodies. Arrows indicate activated
compared between vehicle- and IN19-administered mice (n = 4). Scale bars = 100 mm (SN), 200 mm (CPu). B, The effect of IN19 on caspase-3 activation
after MPTP/P injections. Brain sections, including the SN from wild-type and ATF6a 2/2 mice that were injected with MPTP/P, in the presence or
absence of IN19, were immunostained with the activated caspase 3 and TH antibodies. Nuclei were stained with DAPI. The relative number of
activated caspase 3-positive, TH-positive neurons are shown in the graph. Values shown are the mean 6 S.D. *P,0.05, **P,0.01, compared with
mice without MPTP/P administration. #P,0.05, compared between vehicle- and IN19-administered mice (n = 4). Scale bar = 30 mm. C, The effect of
IN19 on BDNF expression. (I) Brain sections, including the CPu, from wild-type mice that were injected or not injected with MPTP/P, in the presence or
absence of IN19, were immunostained with the BDNF and GFAP antibodies. Nuclei were stained with DAPI. The relative intensity of BDNF or GFAP is
shown in the graph. The intensity of the signals derived from vehicle-administered, not MPTP/P-injected mice, is designated as one. Values shown are
the mean 6 S.D. *P,0.05, compared with mice without MPTP/P administration, #P,0.05, compared between vehicle- and IN19-administered mice
(n = 4). Scale bar = 20 mm. (II) Protein extracts from the CPu of wild-type mice that were injected or not injected with MPTP/P, in the presence or
absence of IN19, were subjected to Western blotting with the indicated antibodies. Relative intensities are shown in the graphs. The intensity of the
signals derived from vehicle-administered mice, not injected with MPTP/P, is designated as one. Values shown are the mean 6 S.D. *P,0.05,
compared with mice without MPTP/P administration. #P,0.05, compared between vehicle- and IN19-administered mice (n = 4).
doi:10.1371/journal.pone.0047950.g006
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(phosphorylated) eIF2a in TH-positive neurons. Scale
bars = 30 mm (A), 20 mm (B).
(TIF)
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